Skip to main content

Advertisement

Table 4 Bone formation and resorption markers

From: Choline-stabilized orthosilicic acid supplementation as an adjunct to Calcium/Vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial

  Placebo ch-OSA
     3 mg Si 6 mg Si 12 mg Si
  Baseline 6 months 12 months Baseline 6 months 12 months Baseline 6 months 12 months Baseline 6 months 12 months
serum OC (ng/mL) 9.74 ± 3.16 9.11 ± 3.73a 7.86 ± 2.26a 10.17 ± 3.91 9.11 ± 3.02a 8.33 ± 2.63a 10.65 ± 3.32 9.74 ± 3.05a 9.08 ± 2.56a 10.16 ± 3.67 9.43 ± 3.02a 8.79 ± 2.82a
serum BAP (U/L) 21.65 ± 6.30 18.91 ± 5.56 18.61 ± 5.56 20.43 ± 7.24 19.61 ± 6.66 18.97 ± 5.98 21.85 ± 6.31 20.59 ± 6.39 20.16 ± 6.01 21.58 ± 7.36 20.19 ± 5.62 19.75 ± 5.96
serum PINP (μg/L) 47.20 ± 13.45 40.83 ± 14.05a 36.49 ± 12.04a 46.28 ± 21.46 40.27 ± 20.18a 35.63 ± 12.34a 44.78 ± 16.07 38.60 ± 13.35a 42.04 ± 12.77a,1,2 48.77 ± 15.09 42.87 ± 11.89a,2 43.73 ± 12.11a,1,2
serum DPD (/Cr) 5.57 ± 3.12 4.77 ± 1.12 4.74 ± 1.28 5.22 ± 1.50 5.17 ± 2.04 4.83 ± 1.62 5.74 ± 1.45 5.81 ± 1.68 5.49 ± 1.70 5.92 ± 1.57 5.36 ± 1.91 6.22 ± 2.62
serum CTX-I (μg/mmol Cr) 359.01 ± 129.89 271.15 ± 124.21 284.66 ± 134.09 331.88 ± 155.87 245.03 ± 107.82 220.71 ± 98.08 349.10 ± 126.71 294.21 ± 137.802 319.38 ± 160.782 360.43 ± 139.00 310.95 ± 122.052 320.99 ± 113.632
  1. Bone formation and resorption markers at baseline (mean ± SD) and after 6 and 12 months supplementation with placebo (Ca/vit D) and three different ch-OSA doses (Si + Ca/vit D; Si: 3, 6, 12 mg/day). a: p < 0.05 (MANCOVA, vs. baseline), 1: p < 0.05 (MANCOVA, vs. placebo) and 2: p < 0.05 (MANCOVA, vs. 3 mg Si).
  2. OC: osteocalcin, BAP: bone specific alkaline phosphatase, PINP: procollagen type I N-terminal propeptide, DPD: deoxypyridinoline, CTX-I: C-terminal collagen type I.